B-ALL Clinical Trial
Official title:
Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B-ALL
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
Status | Recruiting |
Enrollment | 40 |
Est. completion date | July 1, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Signed written informed consent 2. Diagnose as Relapsed and Refractory B -ALL, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory patients ; 3. Relapse after hematopoietic stem cell transplantation; 3. For patients with Ph + ALL, the following conditions must be met: those who have received a standard induction chemotherapy regimen and who have not achieved complete remission after TKI treatment or have relapsed after remission (cannot tolerate TKI treatment or have contraindications to TKI treatment or the presence of TKI class) Except for drug resistant patients) 4. Evidence for cell membrane CD19 or CD22 expression 5. All genders ages: 2 to 75 years 6. The expect time of survive is above 3 months; 7. KPS>60 8. No serious mental disorders ; 9. Left ventricular ejection fraction =50% 10. Sufficient hepatic function defined by ALT/AST=3 x ULN and bilirubin=2 x ULN; 11. Sufficient renal function defined by creatinine clearance=2 x ULN; 12. Sufficient pulmonary function defined by indoor oxygen saturation=92%; 13. With single or venous blood collection standards, and no other cell collection contraindications; 14. Ability and willingness to adhere to the study visit schedule and all protocol requirements. Exclusion Criteria: 1. Previous history of other malignancy; 2. Presence of uncontrolled active infection; 3. Evidence of disorder that need the treatment by glucocorticoids; 4. Active or chronic GVHD 5. The patients treatment by inhibitor of T cell 6. Pregnant or breasting-feeding women; 7. Any situation that investigators regard not suitable for attending in this study (e.g. HIV , HCVinfection or intravenous drug addiction) or may affect the data analysis. |
Country | Name | City | State |
---|---|---|---|
China | 920th Hospital of Joint Logistics Support Force | Kunming | Yunnan |
Lead Sponsor | Collaborator |
---|---|
Chongqing Precision Biotech Co., Ltd |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events that related to treatment | Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) | 2 years | |
Primary | The response rate of CD19 and CD22 prime CAR-T treatment in patients with relapse/refractory B-ALL | The response rate of CD19 and CD22 prime CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline | 6 months | |
Secondary | Rate of prime CAR-T cells in bone marrow | Determine the rate of prime CAR-T cells in bone marrow by flow cytometry | 2 years | |
Secondary | Rate of prime CAR-T cells in peripheral blood | Determine the rate of prime CAR-T cells in peripheral blood by flow cytometry | 2 years | |
Secondary | Quantity of prime CAR copies in bone marrow | Determine the quantity of prime CAR copies in bone marrow by qPCR | 2 years | |
Secondary | Quantity of prime CAR copies in peripheral blood | Determine the quantity of prime CAR copies in peripheral blood by qPCR | 2 years | |
Secondary | Rate of CD19 and CD22 positive cells in Bone marrow | Determine the rate of CD19 and CD22 positive cells in bone marrow by flow cytometry | 1 years | |
Secondary | Levels of IL-6 in Serum | Serological determination of IL-6 | 3 months | |
Secondary | Levels of IL-10 in Serum | Serological determination of IL-10 | 3 months | |
Secondary | Levels of TNF-a in Serum | Serological determination of TNF-a | 3 months | |
Secondary | Levels of CRP in Serum | Serological determination of CRP | 3 months | |
Secondary | Duration of Response (DOR) of CD19 and CD22 prime CAR-T treatment in patients with refractory/relapsed B-ALL | DOR will be assessed from the first assessment of CR/CRi to the first assessment of recurrence or progression of the disease or death from any cause (censored) | 2 years | |
Secondary | Progress-free survival(PFS) of CD19 and CD22 targeted prime CAR-T treatment in patients with refractory/relapsed B-ALL | PFS will be assessed from the first prime CAR-T cell infusion to death from any cause or the first assessment of progression (censored) | 2 years | |
Secondary | Overall survival(OS) of CD19 and CD22 prime CAR-T treatment in patients with refractory/relapsed B-ALL | OS will be assessed from the first primeCAR-T cell infusion to death from any cause (censored) | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04088890 -
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT04546906 -
Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia
|
N/A | |
Recruiting |
NCT04546893 -
Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia
|
N/A | |
Active, not recruiting |
NCT01209286 -
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Withdrawn |
NCT05571540 -
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
|
Phase 1/Phase 2 | |
Completed |
NCT01290120 -
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT03448393 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1 | |
Recruiting |
NCT05350787 -
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL
|
Phase 1 | |
Recruiting |
NCT05350852 -
Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL
|
Phase 1 | |
Recruiting |
NCT05621291 -
A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
|
N/A | |
Active, not recruiting |
NCT04318678 -
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
|
Phase 1 | |
Active, not recruiting |
NCT04499573 -
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
|
Phase 1/Phase 2 | |
Recruiting |
NCT04512716 -
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
|
Early Phase 1 | |
Active, not recruiting |
NCT03751709 -
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL
|
Phase 1 | |
Recruiting |
NCT05639179 -
Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
|
Phase 1/Phase 2 | |
Recruiting |
NCT04792593 -
Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
|
N/A | |
Recruiting |
NCT05442515 -
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02328014 -
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02315612 -
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
|
Phase 1 |